Moxifloxacin
- Generic Name
- Moxifloxacin
- Brand Names
- Avelox, Moxeza, Vigamox
- Drug Type
- Small Molecule
- Chemical Formula
- C21H24FN3O4
- CAS Number
- 151096-09-2
- Unique Ingredient Identifier
- U188XYD42P
- Background
Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment.
- Indication
For the treatment of sinus and lung infections such as sinusitis, pneumonia, and secondary infections in chronic bronchitis. Also for the treatment of bacterial conjunctivitis (pinkeye).
- Associated Conditions
- Acute Exacerbation of Chronic Bronchitis (AECB), Bacterial Conjunctivitis, Community Acquired Pneumonia (CAP), Plague, Postoperative Infections, Postoperative Inflammatory Response, Sinusitis, Skin Infections, Ocular bacterial infections
- Associated Therapies
- -
Study of Ramucirumab (IMC-1121B) Therapy and Corrected QT (QTc) Interval Changes
- Conditions
- Interventions
- First Posted Date
- 2009-11-23
- Last Posted Date
- 2015-06-10
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 68
- Registration Number
- NCT01017731
- Locations
- 🇺🇸
ImClone Investigational Site, Seattle, Washington, United States
Pharmacokinetic and Exploratory Electrocardiogram (ECG) Study
- First Posted Date
- 2009-11-23
- Last Posted Date
- 2009-12-01
- Lead Sponsor
- Mutual Pharmaceutical Company, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT01018420
- Locations
- 🇺🇸
PRACS Institute, Ltd. - Cetero Research, Fargo, North Dakota, United States
Effect on the Electrocardiographic QT Interval Corrected for Heart Rate (QTc) in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2009-09-18
- Last Posted Date
- 2011-01-07
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 62
- Registration Number
- NCT00979316
- Locations
- 🇺🇸
Mds Pharma Services (Us), Inc, Tempe, Arizona, United States
A Phase 1 Study to Investigate the Effects of Talampanel on the Heart Rhythm
- First Posted Date
- 2009-08-25
- Last Posted Date
- 2010-04-07
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 135
- Registration Number
- NCT00964730
- Locations
- 🇺🇸
Cetero Research - Fargo, Fargo, North Dakota, United States
A Comparative Study of Ampicillin/Sulbactam Versus Moxifloxacin in the Treatment of Complicated Intra-abdominal Infections
- Conditions
- Interventions
- First Posted Date
- 2009-08-06
- Last Posted Date
- 2011-08-02
- Target Recruit Count
- 100
- Registration Number
- NCT00952796
- Locations
- 🇨🇳
Kaohsiung Medical University Hospital, Department of Emergency Medicine/Surgery, Kaohsiung, Taiwan
The Effect Of Lersivirine (UK-453,061) On Qt Intervals In Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2009-07-10
- Last Posted Date
- 2010-09-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 66
- Registration Number
- NCT00936871
- Locations
- 🇧🇪
Pfizer Investigational Site, Bruxelles, Belgium
Study Evaluating The Effect of Bosutinib (SKI-606) On Cardiac Repolarization (Rhythms Of The Heart)
- First Posted Date
- 2009-06-04
- Last Posted Date
- 2009-09-02
- Lead Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Target Recruit Count
- 60
- Registration Number
- NCT00914121
Concentration of Besifloxacin, Gatifloxacin, and Moxifloxacin in Human Conjunctiva After Topical Instillation
- Conditions
- Interventions
- First Posted Date
- 2009-05-21
- Last Posted Date
- 2011-12-09
- Lead Sponsor
- Bausch & Lomb Incorporated
- Target Recruit Count
- 119
- Registration Number
- NCT00905762
- Locations
- 🇺🇸
Bausch & Lomb Incorporated, Rochester, New York, United States
Thorough Corrected QT Interval (QTc) Study To Evaluate Possible Effects of Prucalopride on ECG Parameters
- Conditions
- Interventions
- First Posted Date
- 2009-05-18
- Last Posted Date
- 2009-05-18
- Lead Sponsor
- Movetis
- Target Recruit Count
- 120
- Registration Number
- NCT00903747
A Study to Investigate the Potential for AZD5672 to Affect the Electrical Conduction Pathways in the Heart
- Conditions
- Interventions
- First Posted Date
- 2009-04-24
- Last Posted Date
- 2009-07-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 64
- Registration Number
- NCT00887770
- Locations
- 🇬🇧
Research Site, London, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.